High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-nbome designer drugs in urine specimens

Journal of Analytical Toxicology

Volumn 38, Issue 3, 2014, Pages 113-121

  Poklis, Justin L ^a   Clay, Deborah J ^a   Poklis, Alphonse ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,5 DIMETHOXY 3,4 DIMETHYLPHENYL) N (2 METHOXYBENZYL)ETHANAMINE; 2 (2,5 DIMETHOXY 4 METHYLPHENYL) N (2 METHOXYBENZYL)ETHANAMINE; 2 (2,5 DIMETHOXYPHENYL) N (2 METHOXYBENZYLIDENE)ETHANAMINE; 2 (4 IODO 2,5 DIMETHOXYPHENYL) N [(2,3 METHYLENEDIOXYPHENYL)METHYL]ETHANAMINE; DESIGNER DRUG; N (2 FLUOROBENZYL) 2 (4 IODO 2,5 DIMETHOXYPHENYL)ETHANAMINE; N (2 METHOXYBENZYL) 2,5 DIMETHOXY 4 BROMOPHENETHYLAMINE; N (2 METHOXYBENZYL) 2,5 DIMETHOXY 4 CHLOROPHENETHYLAMINE; N (2 METHOXYBENZYL) 2,5 DIMETHOXY 4 IODOPHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG ABUSE; DRUG OVERDOSE; DRUG STABILITY; EMERGENCY WARD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; QUADRUPOLE MASS SPECTROMETRY; RELIABILITY; REPRODUCIBILITY; SIGNAL NOISE RATIO; SOLID PHASE EXTRACTION COLUMN; TANDEM MASS SPECTROMETRY; UNITED STATES; URINALYSIS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESIGNER DRUGS; FORENSIC TOXICOLOGY; HALLUCINOGENS; HUMANS; LIMIT OF DETECTION; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; SPECIMEN HANDLING; TANDEM MASS SPECTROMETRY;

EID: 84896084852     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bku005     Document Type: Article

References (24)

1. Geyer, M.A., Vollenweider, F.X. (2008) Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences, 29, 445-453.
2. Abbas, A., Roth, B.L. (2008) Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opinion on Pharmacotherapy, 9, 3251-3259.
3. Nichols, D.E. (2004) Hallucinogens. Pharmacology and Therapeutics, 101, 131-181.
4. Shulgin, A.T., Carter, M.F. (1975) Centrally active phenethylamines. Psychopharmacol Commun, 1, 93-98.
5. Shulgin, A., Shulgin, A. (1991) PIHKAL: A Chemical Love Story. Transform Press: Berkeley, CA.
6. Dean, B.V., Stellpflug, S.J., Burnett, S.M., Engebretsen, K.M. (2013) 2C or not 2C: phenethylamine designer drug review. Journal of Medical Toxicology, 9, 172.
7. Glennon, R.A., Kier, L.B., Shulgin, A.T. (1979) Molecular connectivity analysis of hallucinogenic mescaline analogs. Journal of Pharmaceutical Sciences, 68, 906-907.
8. Zuba, D., Sekua, K. (2013) Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 8, 634-645.
9. Zuba, D., Sekula, K., Buczek, A. (2013) 25C-NBOMe-new potent hallucinogenic substance identified on the drug market. Forensic Science International, 227, 7-14.
10. Sekua, K., Zuba, D. (2013) Structural elucidation and identification of a new derivative of phenethylamine using quadrupole time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 18, 2081-2090.
11. Braden, M.R., Parrish, J.C., Naylor, J.C., Nichols, D.E. (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology, 70, 1956-1964.
12. Nichols, D.E., Frescas, S.P., Chemel, B.R., Rehder, K.S., Zhong, D., Lewin, A.H. (2008) High specific activity tritium-labeled N-(2-methoxybenzyl)- 2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorganic and Medicinal Chemistry, 16, 6116-6123.
13. Ettrup, A., Holm, S., Hansen, M.,Wasim,W., Santini, M.A., Palner, M. et al. (2013) Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [11C]Cimbi-36. Molecular Imaging and Biology, 15, 376.
14. 2013) Erowid. 25IeNBOMe (2C-I-NBOMe) Dose. http://www. erowid.org/chemicals/2ci_nbome/2ci_nbome_dose.shtml (accessed Aug 10, 2013).
15. Rose, S.R., Cumpston, K.L., Stromberg, P.E., Wills, B.K. (2012) Severe poisoning following self-reported use of 25-I, a novel substituted amphetamine. Clinical Toxicology (Philadelphia), 50, 707-708.
16. Kelly, A., Eisenga, B., Riley, B., Judge, B. (2012) Case series of 25I-NBOMe exposures with laboratory confirmation. Clinical Toxicology (Philadelphia), 50, 702.
17. Rose, S.R., Cumpston, K.L., Stromberg, P.E., Wills, B.K. (2012) Severe poisoning following self-reported use of 25-I, a novel substituted amphetamine. Clinical Toxicology (Philadelphia), 50, 707-708.
18. Rose, R.S., Poklis, J.L., Poklis, A. (2013) A case of 25I-NBOMe (25-I) intoxication: a new potent 5HT2a agonist designer drug. Clinical Toxicology (Philadelphia), 51, 174-177.
19. Hill, S.L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M. et al. (2013) Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clinical Toxicology (Philadelphia), 51, 487-492.
20. Stellpflug, S.J., Kealey, S.E., Hegarty, C.B., Janis, G.C. (2013) 2-(4-Iodo- 2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. Journal of Medical Toxicology, doi:10.1007/s13181-013-0314-y.
21. Poklis, J.L., Nanco, C.R., Troendle, M.M., Wolf, C.E., Poklis, A. (2013) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)- methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Testing and Analysis, doi:10.1002/dta.1522.
22. US Food and Drug Administration. (2001) Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD. 22. 2013) Report from the Scientific Working Group for Forensic Toxicology: Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. Journal of Analytical Toxicology, 37, 452-474.
23. Poklis, J.L., Charles, J., Wolf, C.E., Poklis, A. (2013) High performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomedical Chromatography, doi:10.1002/bmc.2999.
24. Poklis, J.L., Devers, K.G., Arbefeville, E.F., Julia, M., Pearson, J.M., Houston, E. et al. (2013) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5- dimethoxyphenyl)-N-[(2 methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death, Forensic Science International. doi:10.1016/j.forsciint.2013.10.015.